This HTML5 document contains 193 embedded RDF statements represented using HTML+Microdata notation.

The embedded RDF content will be recognized by any processor of HTML5 Microdata.

Namespace Prefixes

PrefixIRI
dctermshttp://purl.org/dc/terms/
dbohttp://dbpedia.org/ontology/
foafhttp://xmlns.com/foaf/0.1/
n4http://dbpedia.org/resource/File:
n18https://global.dbpedia.org/id/
dbthttp://dbpedia.org/resource/Template:
rdfshttp://www.w3.org/2000/01/rdf-schema#
freebasehttp://rdf.freebase.com/ns/
n6http://commons.wikimedia.org/wiki/Special:FilePath/
rdfhttp://www.w3.org/1999/02/22-rdf-syntax-ns#
owlhttp://www.w3.org/2002/07/owl#
wikipedia-enhttp://en.wikipedia.org/wiki/
dbphttp://dbpedia.org/property/
dbchttp://dbpedia.org/resource/Category:
provhttp://www.w3.org/ns/prov#
xsdhhttp://www.w3.org/2001/XMLSchema#
goldhttp://purl.org/linguistics/gold/
wikidatahttp://www.wikidata.org/entity/
dbrhttp://dbpedia.org/resource/

Statements

Subject Item
dbr:Direct_thrombin_inhibitor
dbo:wikiPageWikiLink
dbr:Discovery_and_development_of_direct_thrombin_inhibitors
Subject Item
dbr:Discovery_and_development_of_beta-blockers
dbo:wikiPageWikiLink
dbr:Discovery_and_development_of_direct_thrombin_inhibitors
Subject Item
dbr:Discovery_and_development_of_direct_thrombin_inhibitors
rdf:type
dbo:Drug
rdfs:label
Discovery and development of direct thrombin inhibitors
rdfs:comment
Direct thrombin inhibitors (DTIs) are a class of anticoagulant drugs that can be used to prevent and treat embolisms and blood clots caused by various diseases. They inhibit thrombin, a serine protease which affects the coagulation cascade in many ways. DTIs have undergone rapid development since the 90's. With technological advances in genetic engineering the production of recombinant hirudin was made possible which opened the door to this new group of drugs. Before the use of DTIs the therapy and prophylaxis for anticoagulation had stayed the same for over 50 years with the use of heparin derivatives and warfarin which have some well known disadvantages. DTIs are still under development, but the research focus has shifted towards factor Xa inhibitors, or even dual thrombin and fXa inhibi
foaf:depiction
n6:Ximelagatran_activation.svg n6:Svømmende_blodigle.jpg n6:Coagulation_full.svg n6:Argatroban_pocket_binding.jpg n6:Bivalirudin.png n6:Hirudin_in_complex_with_thrombin.png n6:Dabigatran_etexilate_and_dabigatran.jpg n6:Lepirudin_sequence.svg
dcterms:subject
dbc:Drug_discovery dbc:Direct_thrombin_inhibitors dbc:Anticoagulants
dbo:wikiPageID
37120076
dbo:wikiPageRevisionID
1124890849
dbo:wikiPageWikiLink
dbr:Extravascular_compartment dbr:Sulfate dbr:Amidinium n4:Ximelagatran_activation.svg dbr:Platelets dbr:Dose-response_curve dbr:Peptidomimetic dbr:Hydrogen_bond dbr:Food_and_Drug_Administration dbr:Glycine dbr:Vitamin_K_antagonists dbr:Atrial_fibrillation dbr:Guanidine dbr:Steric_effects dbr:Catalysis dbr:Stoichiometric dbr:John_Berry_Haycraft dbr:Arginine dbr:Cytochrome_P450 dbr:Factor_X dbr:Naphthalene dbr:Factor_XIII dbr:Food_and_drug_administration dbr:Histidine dbr:Leucine dbr:Anticoagulant dbr:Myocardial_infarction dbr:Piperidine dbr:Amino-terminal dbr:Factor_V dbr:Coagulation dbr:Factor_VIII dbr:Biliary_system dbr:Venous_thrombosis dbr:Antidote dbr:Mitsubishi_Tanabe_Pharma dbr:Excretion dbr:Aliphatic_compound dbr:Antithrombin dbr:Polypeptide dbr:Interaction dbr:Meta-analysis dbr:Knee_replacement n4:Hirudin_in_complex_with_thrombin.png dbr:Preventive_medicine dbr:Drug_development dbr:William_Henry_Howell dbr:Therapy dbc:Drug_discovery dbr:Metabolism dbr:Boehringer_Ingelheim dbr:Stroke dbr:Acid_dissociation_constant dbr:Lipophilicity dbr:Mechanism_of_action dbr:Subcutaneous_tissue dbc:Direct_thrombin_inhibitors dbr:Renal_clearance dbr:Ester dbr:Derivative_(chemistry) dbr:Blood_plasma dbr:Anticoagulation dbr:Platelet_factor_4 dbr:Proteolysis dbr:Ximelagatran dbr:Active_site dbr:Zymogen dbr:Hydrophobe dbr:Carboxylate dbr:Therapeutic_index dbr:Protein_domain dbr:Low_molecular_weight_heparin dbr:Fibrinogen dbr:Hirudin dbr:Thrombin dbr:Valence_(chemistry) dbr:Clinical_trial dbr:Aromaticity dbr:Immune-mediated dbr:Heparin-induced_thrombocytopenia dbr:Divalent n4:Chemical_structure_of_NAPAP.tif dbr:Fibrin dbr:Hepatic_impairment dbr:C-terminus dbr:Toxicity dbr:In_vitro n4:Bivalirudin.png dbr:Bolus_(medicine) dbr:Bayer dbr:Benzamidine dbr:Deep_vein_thrombosis dbr:Hirudo_medicinalis dbr:Factor_XI dbr:Heparin dbr:Desirudin dbr:Hepatic dbr:Thrombus dbr:Beta_barrel dbc:Anticoagulants dbr:Factor_VII dbr:Isoleucine n4:Lepirudin_sequence.svg dbr:Argatroban dbr:Proline dbr:Blood_vessel dbr:X-ray_crystallography dbr:Venous_thromboembolism dbr:Benzimidazole dbr:Binding_affinity dbr:Dabigatran n4:Thrombin_binding_sites.tiff dbr:Tissue_factor dbr:Chronic_kidney_disease dbr:Bivalirudin dbr:Oral_administration dbr:Acute_coronary_syndrome dbr:Parenteral dbr:Carbamate dbr:Percutaneous_coronary_intervention dbr:Blood_clots dbr:Human_gastrointestinal_tract dbr:Prospective_studies dbr:Enoxaparin dbr:AstraZeneca dbr:Disease dbr:Structural_analog dbr:Aspartic_acid dbr:Cofactor_(biochemistry) dbr:Exosite_(biology) dbr:Biological_half-life n4:Argatroban_pocket_binding.jpg dbr:Genetic_engineering dbr:Dabigatran_etexilate dbr:Serine_protease dbr:Randomized_trial dbr:Intravenous_therapy dbr:Direct_Xa_inhibitor dbr:Embolism n4:Svømmende_blodigle.JPG dbr:Warfarin dbr:Lepirudin dbr:Tryptophan dbr:Crystal_structure dbr:Hip_replacement dbr:Prodrug dbr:Indication_(medicine) dbr:Enzyme_substrate n4:Coagulation_full.svg dbr:Serine dbr:Peptide n4:Dabigatran_binding_pockets.tiff n4:Dabigatran_etexilate_and_dabigatran.jpg dbr:Dissociation_constant dbr:Absorption_(pharmacokinetics) dbr:Intravenous dbr:Dodecapeptide dbr:Drug_target
owl:sameAs
freebase:m.0n4cjdb wikidata:Q5281999 n18:4iSQb
dbp:wikiPageUsesTemplate
dbt:Antithrombotics dbt:Cn dbt:Drug_design dbt:Reflist
dbo:thumbnail
n6:Svømmende_blodigle.jpg?width=300
dbo:abstract
Direct thrombin inhibitors (DTIs) are a class of anticoagulant drugs that can be used to prevent and treat embolisms and blood clots caused by various diseases. They inhibit thrombin, a serine protease which affects the coagulation cascade in many ways. DTIs have undergone rapid development since the 90's. With technological advances in genetic engineering the production of recombinant hirudin was made possible which opened the door to this new group of drugs. Before the use of DTIs the therapy and prophylaxis for anticoagulation had stayed the same for over 50 years with the use of heparin derivatives and warfarin which have some well known disadvantages. DTIs are still under development, but the research focus has shifted towards factor Xa inhibitors, or even dual thrombin and fXa inhibitors that have a broader mechanism of action by both inhibiting factor IIa (thrombin) and Xa. A recent review of patents and literature on thrombin inhibitors has demonstrated that the development of allosteric and multi-mechanism inhibitors might lead the way to a safer anticoagulant.
gold:hypernym
dbr:Drugs
prov:wasDerivedFrom
wikipedia-en:Discovery_and_development_of_direct_thrombin_inhibitors?oldid=1124890849&ns=0
dbo:wikiPageLength
34132
foaf:isPrimaryTopicOf
wikipedia-en:Discovery_and_development_of_direct_thrombin_inhibitors
Subject Item
dbr:Hirudin
dbo:wikiPageWikiLink
dbr:Discovery_and_development_of_direct_thrombin_inhibitors
Subject Item
dbr:Discovery_and_Development_of_Direct_Thrombin_Inhibitors
dbo:wikiPageWikiLink
dbr:Discovery_and_development_of_direct_thrombin_inhibitors
dbo:wikiPageRedirects
dbr:Discovery_and_development_of_direct_thrombin_inhibitors
Subject Item
wikipedia-en:Discovery_and_development_of_direct_thrombin_inhibitors
foaf:primaryTopic
dbr:Discovery_and_development_of_direct_thrombin_inhibitors